Compared to patients with paroxysmal atrial fibrillation, those with persistent AF typically exhibit significantly lower HSPB1 expression levels, making them a more responsive target population for HSP inducer therapy. This evidence concerns the gene HSP90B2P and Paroxysmal atrial fibrillation.